Morning Trend | Incyte's momentum slows down, will it rebound after a short-term pullback?
Incyte (INCY.US) has recently experienced a continuous rise over the past few days, and the short-term market atmosphere has noticeably warmed up. Yesterday, the trading volume expanded during the session, but there was a slight pullback at the close, leading to subtle divergences in the sentiment of following funds. There are discussions in the community: "Should we wait for a pullback to make a low buy? Or is the main force preparing to directly pull up for a second wave?" After all, such popular pharmaceutical stocks can easily attract funds with any slight movement. Notably, the small upward lines accumulated near the 60-day moving average over the past two weeks indicate a strengthening of fund clustering, with technical traders focusing on whether the support above $88 can be maintained. If it pulls back to the "safe zone" of $93-95, there may be an opportunity for a rebound. The market is still in a tug-of-war over its new drug pipeline and merger expectations, with a recent increase in risk appetite for small-cap pharmaceutical stocks, as aggressive funds are eager for the next main rise or to seize a rebound. However, short-term uncertainties remain high, and the market may experience repeated fluctuations—high-level selling pressure and news interference cannot be ignored. If the pharmaceutical legend's "old routine" reappears—opening high, surging, then pulling back before rising again—some technical traders may have the chance to buy low for arbitrage, while funds that missed the opportunity will also chase the rhythm to add positions. Overall, whether the main rising wave can continue still requires close attention to fund flow speed, intraday market conditions, and the overall demonstration effect of the sector. Short-term operation suggests maintaining flexible positions and locking in profits in a timely manner
Technical Forecast·
